CROs offering Japan PMDA Regulatory Strategy with Biologics (Other)
Japan PMDA Regulatory Strategy combined with Biologics (Other) is a common shortlist filter for sponsors evaluating CRO partners. This explore page lists organizations that publicly map to both dimensions, so you can move from taxonomy browsing to a tighter candidate set without rebuilding filters from scratch.
Profiles here are fit-first: open each listing for scope, geography, regulatory posture, and provenance-backed facts. The directory does not rank these rows as a single "best" answer — use them to assemble a right-sized outreach list for your program stage and quality bar.
When you need adjacent criteria (indications, claim status, or cross-category search), continue to the main search experience and layer filters on top of this service × modality starting point.
Auto-generated by BioBM Editorial AI.
Matching companies
- Aragen Life Sciences
Global CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
- Certara
Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
- Fortrea
Fortrea is a global Contract Research Organization (CRO) with over 30 years of clinical development expertise. The company delivers comprehensive Phase I through Phase IV study management, clinical pharmacology services, and market access solutions to biopharma, biotech, and…
- ICON
ICON is a CRO with 8,000 biotech-dedicated professionals offering end-to-end clinical development, consulting, and therapeutic expertise across all development phases.
- IQVIA Real-World Solutions
IQVIA Real-World Solutions leverages 64+ petabytes of proprietary data and 1.2B+ non-identified patient records to accelerate clinical trial site identification and enable evidence-based solutions across 100+ countries.
- Medpace
Medpace is a full-service contract research organization (CRO) dedicated to accelerating the development of safe and effective medical therapeutics. The company operates under a therapeutically-focused, integrated model that provides sponsors with early and ongoing insight…
- Novotech
Global full-service CRO specializing in early-phase and oncology trials across 50+ countries, with expertise in cardiovascular, cell and gene therapy, and radiopharmaceutical development.
- PPD
PPD is a leading global contract research organization (CRO) and the clinical research business of Thermo Fisher Scientific. The organization provides comprehensive drug development, laboratory, and lifecycle services to pharmaceutical, biotechnology, medical device,…
- Pharmaron
Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- Premier Research
Premier Research is a global full-service CRO delivering clinical research and development solutions across the complete drug development lifecycle. The organization provides comprehensive capabilities spanning study design, study startup, medical affairs, biostatistics and data management, central monitoring, clinical monitoring and site management, project and risk management, safety and pharmacovigilance, quality and compliance, and medical writing.
- Syngene International
Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
- WuXi AppTec
Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Related: Japan PMDA Regulatory Strategy service page · Biologics (Other) modality page
Markdown mirror: /explore/svc_regulatory_japan_pmda/mod_biologics_other.md